Titre : | Prevalence of hepatitis C among injection drug users in England and Wales : Is harm reduction working ? Hepatitis C. (2001) |
Auteurs : | Vivian-D HOPE ; Linda DONOVAN ; Onoël GILL ; Matthew HICKMAN ; Gillian HUNTER ; Steve JONES ; A.L.I. JUDD ; Theresa LAMAGNI ; John-V PARRY ; Gerry-V STIMSON ; Centre for Research on Drugs and Health Behaviour. Department of Social Science and Medicine. Imperial College School of Medicine. London. GBR ; Communicable Disease Surveillance Centre. Public Health Laboratory Service. London. GBR ; Virus Reference Division. Public Health Laboratory Service. London. GBR |
Type de document : | Article |
Dans : | American journal of public health (vol. 91, n° 1, 2001) |
Pagination : | 38-42 |
Langues: | Anglais |
Mots-clés : | Hépatite virale C ; Virose ; Infection ; Epidémiologie ; Prévalence ; Toxicomanie ; Angleterre ; Grande Bretagne ; Royaume Uni ; Europe ; Pays de Galles ; Toxicomane ; Homme ; Facteur risque ; Appareil digestif [pathologie] ; Foie [pathologie] |
Résumé : | [BDSP. Notice produite par INIST cCR0x4qb. Diffusion soumise à autorisation]. Objectives. This study sought to establish the prevalence of hepatitis C antibodies (anti-HCV) and hepatitis B antibodies (anti-HBc) among injection drug users in England and Wales. Methods. A voluntary cross-sectional survey collected oral fluid samples and behavioral information ; 2203 injectors were recruited through drug agencies, and 758 were recruited in the community. Results. Prevalence was 30% for anti-HCV, 21% for anti-HBc, and 0.9% for HIV antibodies. Anti-HCV prevalence rates were significantly greater among those with longer injecting careers, those in older age groups, those residing in London, those recruited in drug agencies, those positive for anti-HBc, and those with a previous voluntary HIV test. Conclusions. Anti-HCV prevalence rates among injectors in England and Wales, where comprehensive harm reduction programs exist, are lower than rates in other industrialized countries. |